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Genomic complexity and IGHV mutational status
are key predictors of outcome of chronic 
lymphocytic leukemia patients with TP53 disruption
The clinical course of chronic lymphocytic leukemia
(CLL) is extremely heterogeneous and while some patients
achieve a normal lifespan, others succumb to the disease
shortly after diagnosis. Recurrent chromosomal aberrations
as detected by chromosome banding analysis (CBA) or flu-
orescent in situ hybridization (FISH) have a reproducible
prognostic power in terms of response to therapy and sur-
vival.1-3 In particular, patients whose tumor cells harbor 17p
deletions (17p-) are considered to have a shorter survival
and, hence, high-risk CLL. This poor prognosis is, however,
not universally true for all patients with 17p- CLL. Indeed,
we and others have observed that some clinical-biological
features, such as presence of B symptoms, advanced clinical
stage, size of the 17p- clone, β2-microglobulin (β2M) con-
centration and IGH mutational status have a significant
impact on the outcome of this subgroup of patients.4,5
Novel molecular studies have helped in the understanding
of 17p- CLL. On one hand, TP53 mutations are present in
more than 80% of cases with 17p deletion and in around
5% of patients without 17p deletion.6,7 On the other hand,
next generation sequencing studies have revealed novel
genetic aberrations such as NOTCH1 and SF3B1mutations
that have a negative impact on survival.8-10 Finally, genomic
complexity, as defined by karyotyping1 or copy number
(CN) arrays, has also been independently associated with
disease transformation and poor outcome in patients with
CLL.11,12 The aim of this study was to evaluate the prognos-
tic value of concomitant molecular abnormalities in
patients with CLL and TP53 aberrations as diagnosed by
FISH, CBA or DNA sequencing.
From our database, we identified 55 of 763 (7%) CLL
patients with TP53 disruption detected at any time over the
course of the disease. Importantly, CBA/FISH and molecu-
lar studies were performed on samples drawn on the same
date. Other clinical and biological characteristics, such as
Binet stage, CD38 and ZAP70 expression or β2M serum
concentration, were also analyzed at the time of detection
of TP53 disruption using conventional methods. All
patients from this study signed an informed consent and
were recruited into the International Cancer Genome
Consortium Chronic Lymphocytic Leukemia project,
which was reviewed by the Institutional Review Board.
CBA was performed on Giemsa-banded chromosomes
obtained after a 72-h culture and stimulation with tetrade-
canoyl-phorbol-acetate. A complex karyotype was defined
as the presence of 3 or more clonal chromosomal aberra-
tions. FISH studies for 11q, 13q and 17p deletions and gains
of chromosome 12 were performed using the Vysis CLL
probe kit (Abbott, Des Plaines, IL, USA). IGHV-IGHD-IGHJ
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Figure 1. Graphical representation of the whole cohort of patients according to TP53 alterations. The percentage of cells with 17p deletion
by FISH is illustrated in the vertical bar plots. The squares below indicate the presence of 17p losses by copy number arrays (red: loss;
green: copy number neutral loss of heterozygosity; gray: wild type; white: not available); copy number alterations; 17p deletions by chro-
mosome banding analysis (red: presence; gray: absence; white: not available); complex karyotype by chromosome banding analysis (red:
presence; gray: absence; white: not available); TP53mutations by sequencing (red: presence; gray: absence; white: not available); NOTCH1
mutations by sequencing (red: presence; gray: absence; white: not available); SF3B1 mutations by sequencing (red: presence; gray:
absence; white: not available); IGHV mutational status by sequencing (red: unmutated; gray: mutated; white: not available); CD38 expres-
sion (red: high; gray: low; white: not available); ZAP70 expression (red: high; gray: low; white: not available); type of TP53 disruption (red:
de novo; gray: acquired).
rearrangements and mutational status and TP53 mutation
analysis were analyzed following ERIC recommenda-
tions.13,14 NOTCH1 and SF3B1mutations were evaluated as
previously described.8,9 CN analysis was performed using
two different platforms: a custom Agilent 8x60K oligonu-
cleotide array (I Salaverria et al., manuscript in preparation)
and the Genome-Wide Human SNP Array 6.0 (Affymetrix,
Santa Clara, CA, USA). Nexus 6.0 Discovery Edition
(Biodiscovery, El Segundo, CA, USA) was used for global
analysis and visualization. All data have been up-loaded to
the GEO database (GSE56277).
Comparison between groups was performed using
Fisher’s exact and Mann-Whitney tests. Overall survival
(OS) and time to first treatment (TTFT) were calculated
from the date of sampling to the date of death or front-line
treatment, respectively, or last follow up. Appropriate cut-
off points for copy number alterations (CNAs) were calcu-
lated using maximally selected rank statistics. Cox regres-
sion multivariate models were fitted in order to assess the
independent prognostic value of those covariates that were
significant by univariate analysis. 
Data were collected from 55 patients with TP53 disrup-
tion (Figure 1). Thirty-four patients had 17p- diagnosed by
interphase FISH and 6 by CBA before the availability of
FISH. The remaining 15 patients were identified to have
TP53 mutations by Sanger sequencing but had no identifi-
able 17p deletion by CBA and/or FISH. Thirty (55%)
patients had de novo aberrations (i.e. detected within 6
months of CLL diagnosis) and 25 (45%) acquired them at a
median of 58 months from diagnosis (range 8-194 months),
23 of these patients (92%) after CLL-specific therapy.
Median age of the entire population was 67 years (range
30-98 years) when the TP53 disruption was detected.
Patients with acquired aberrations had a higher incidence
of Binet stage B-C disease and elevated β2M concentration
at the time of detection of TP53 disruption, consistent with
a more advanced disease (Online Supplementary Table S1).
CBA was performed in 48 patients and yielded adequate
metaphases in 45 of them (Figure 1). Chromosome abnor-
malities involving 17p were observed in 27 of 45 (60%)
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Figure 2. Copy number profiles of
cases with de novo (A) and
acquired (B) TP53 disruption. In
the x-axis the chromosomes are
represented horizontally from 1
to 22, in the y-axis the percent-
age of cases showing the copy
number alterations. Gains are
represented in the positive y-axis
and colored in blue, whereas
losses are represented in the
negative y-axis in red.
Figure 3. (A) Time to first treatment in patients with de novo TP53
disruption according to IGHV mutational status [(mutated (n = 6)
vs. unmutated (n = 20)]; (B) overall survival in patients with TP53
disruption according to the number of copy number alterations 
[0-3 (n=18) vs.4-9 (n=15) vs. more than 9 (n=8)]. 
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patients (Online Supplementary Table S1), and 23 of 45
(52%) patients had a complex karyotype.
In the 34 patients with a positive FISH test, the median
percentage of 17p- cells was 40% (range 10-98%). Forty-
two cases were studied by CN-arrays: 27 using SNP arrays
6.0 and 15 using a customized 8x60K array (Figure 2 and
Online Supplementary Table S2). CN-arrays revealed 17p
losses in 27 of 42 (64%) patients. Furthermore, 17p losses
were more frequent in patients with 25% or more cells
with deletion by FISH compared to patients with a lower
allelic burden (93% vs. 24%; P<0.001). Indeed, CN-arrays
only failed to detect a 17p loss in one out of 15 patients
with 25% or more 17p- cells by FISH, which is considered
the limit of detection of CN-arrays.11 In addition, CN-arrays
were able to detect a copy number neutral loss of heterozy-
gosity (CNN-LOH) of the 17p region in 2 of 14 (14%)
patients who had TP53mutations without 17p deletion by
FISH (Online Supplementary Figure S1). The presence of
other genomic aberrations that have been reported to con-
fer prognostic value independently of TP53 disruption,
such as gains at 2p and 8q or losses at 8p,15was too low in
our series (6%, 9% and 6%, respectively) to have any prog-
nostic impact. 
The number of CNAs was equally distributed among
patients with de novo and acquired TP53 disruption (Online
Supplementary Table S1). The maxstat analysis revealed two
possible cut offs for CNAs with a high prognostic power:
three and nine CNAs per case (Online Supplementary Figure
S2). For the validation of the cut offs, prediction error
curves for their different values were estimated using a
.632+ bootstrap strategy. The integrated Brier score
between time 0 and time 54 of each estimated curve was
used as a performance measure of the corresponding cut
offs (Online Supplementary Figure S3). 
There was a significant correlation between the presence
or absence of a complex karyotype by CBA and the num-
ber of CNAs by CN-array (P=0.011, Mann-Whitney test).
TP53 mutations were detected in 43 of 55 (78%) patients.
NOTCH1 and SF3B1mutations were identified in 10 of 54
(19%) and 8 of 49 (16%) patients, respectively, but no clear
association was evident between the presence of these
mutations and any other genomic aberration and/or prog-
nostic marker. The great majority (86%) of patients with
17p disruption by CN-arrays (either 17p loss or CNN-LOH)
also had concurrent TP53mutations.
Among patients with de novo TP53 disruption, 21 of 30
(70%) required CLL-specific therapy (Online Supplementary
Table S4). Median TTFT was nine months, and covariates
predictive of a shorter TTFT were unmutated IGHV genes
(P=0.011) and high ZAP70 expression (P=0.011).
Multivariate analysis revealed that IGHVmutational status
was the only variable with independent prognostic value in
terms of TTFT (hazard ratio [HR] 13.8, 95% confidence
interval [CI] 1.7-112.9; P=0.014) (Figure 3A). Median over-
all survival for the entire cohort was 37 (95%CI: 34-41)
months from the time of sampling. We tested both possible
cut offs for CNAs (three and nine alterations) and found
that both were equally significant (P=0.024). By multivari-
ate analysis, the only factor with independent prognostic
value was the number of CNAs (0-3 vs. 4-9 vs. >9; P=0.024)
(Figure 3B). Hazard ratios for CNAs were 7.63 (95%CI: 1.6-
37.0; P=0.011) for the 0-3 versus 4-9 comparison and 7.35
(95%CI: 1.62-33.3; P=0.010) for the 4-9 versus >9 compari-
son (Online Supplementary Table S5).
In conclusion, the prognosis of CLL patients with a TP53
disruption is modulated by their genomic complexity as
assessed by CN-arrays but also by additional molecular fea-
tures such as IGHV mutations. Genomic complexity as
determined by CN-arrays was predictive of OS and IGHV
mutational status was predictive of TTFT, which is in keep-
ing with previous results.11 Finally, SNP-arrays were very
helpful in the detection of 17p CNN-LOH. These results
require validation but provide further evidence of the
expanding role of CN-arrays and molecular testing in the
prognostic workup of patients with CLL. 
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